For nearly a decade, the difficulties associated with both the determination and reproducibility of Ras-dependency indexes (RDIs) have limited their application and further delineation of the biology underlying Ras dependency. In this report, we describe the application of a computational single sample gene set enrichment analysis (ssGSeA) method to derive RDis with gene expression data. The computationally derived RDIs across the Cancer Cell Line Encyclopedia (CCLE) cell lines show excellent agreement with the experimentally derived values and high correlation with a previous inhouse siRNA effector node (siREN) study and external studies. Using EMT signature-derived RDIs and data from cell lines representing the extremes in RAS dependency, we identified enriched pathways distinguishing these classes, including the Fas signaling pathway and a putative Ras-independent pathway first identified in NK cells. Importantly, extension of the method to patient samples from The Cancer Genome Atlas (TCGA) showed the same consensus differential expression patterns for these two pathways across multiple tissue types. Last, the computational RDIs displayed a significant association with TCGA cancer patients' survival outcomes. Together, these lines of evidence confirm that our computationally derived RDIs faithfully represent a measure of Ras dependency in both cancer cell lines and patient samples. The application of such computational RDIs can provide insights into Ras biology and potential clinical applications. The Ras genes (KRAS, NRAS, HRAS) are the most frequently mutated oncogenes in human cancers, with KRAS showing the highest overall mutation frequencies 1,2. Although KRAS mutations mainly occur in pancreatic, lung, and colon cancers, Ras gene mutations and amplifications are also found in many other cancer types. Given the significant role of these mutations, full-scale efforts to advance our understanding of Ras biology are underway with the hope of providing insights into oncogenesis mechanisms that will provide benefits for cancer diagnosis and treatment 2-5. Nearly a decade ago, efforts were made to investigate the oncogene "addiction" phenomenon, whereby tumors require the sustained expression and activity of a single aberrantly activated oncogene 6. These efforts led to the classification of cancer cell lines into two categories: Ras dependent and Ras independent 7. To assess variable KRAS dependency across a panel of KRAS mutant human cancer cell lines, Ras dependency indexes (RDIs) were proposed and measured experimentally to examine cancer cell addiction to oncogenic KRAS in a quantitative manner 7. Many molecular features that distinguish KRAS-dependent and KRAS-independent cancer cell lines have been uncovered. For example, PI-3 kinase activation was found to contribute to the loss of KRAS dependency in a context-specific manner 7. Similarly, KRAS dependency was found to be strongly linked to epithelial